<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01785628</url>
  </required_header>
  <id_info>
    <org_study_id>DMR98-IRB-296</org_study_id>
    <nct_id>NCT01785628</nct_id>
  </id_info>
  <brief_title>The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will investigate the effect of pharmacological and electric modulation of
      N-methyl-D-aspartate (NMDA) pathway on the cognitive flexibility and volitional movement
      preparation in patients with Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcosine (also called N-methylglycine) is an endogenous GlyT-1 inhibitor. By blocking
      glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor
      function. NMDA receptor, a subtype of ionotropic glutamate receptors, serves important
      functions in the brain, including learning, memory, cognition, and neural plasticity under
      physiological conditions and contributes to neurodegeneration in pathophysiological
      processes. NMDA receptor represents collectively a group of heteromeric tetramers. Every NMDA
      receptor is a protein complex, typically composed of two NR1 subunits and two NR2 subunits
      that together form the NMDA receptor ion channel. It requires two receptor agonists
      (glutamate for the NR2 binding site and glycine for the NR1 binding site) to open the ion
      channel for NMDA receptor activation. Clinically, modulation through the NMDA-NR1-glycine
      site is preferred to avoid the excitotoxicity associated with the glutamate site activation.8
      In addition, recent animal studies have shown that dopamine secretion can be enhanced by
      either blocking the striatal NR2 or by activation of the NMDA-receptor glycine site. In the
      project, we will focus on pharmacological enhancement of NMDA-glycine receptor function based
      on increasing synaptic glycine concentration by sarcosine administration to examine whether
      enhancing NMDA-glycine receptor activity can improve the neuropsychiatric symptoms, cognition
      and hopefully motor function in PD-D patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks.</time_frame>
    <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Abilities Screening Instrument (CASI) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Dementia Rating (CDR) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment &amp; Problem Solving, Community Affairs, Home &amp; Hobbies, and Personal Care. With a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychiatry Inventory (NPI) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory-II (BDI-II) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in The 39-item Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Brain Imaging by 18F-FDG PET From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>18F-FDG PET scan : 8 patients for treatment and placebo groups,respectively.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Brain Imaging by [99mTc]TRODAT-1 From Baseline to 8 Weeks.</measure>
    <time_frame>baseline to 8 weeks</time_frame>
    <description>[99mTc]TRODAT-1 : 7 patients for treatment and placebo groups, respectively.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Parkinson's Disease With Dementia</condition>
  <arm_group>
    <arm_group_label>Sarcosine capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sarcosine Capsule</intervention_name>
    <description>Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.</description>
    <arm_group_label>Sarcosine capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Placebo is dextrin composition.</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of PD-D will be based on the criteria proposed by 2007 movement
             disorders PD-D task force. (Emre M et.al. Mov Disord 2007; 22:1689-1707)

        Exclusion Criteria:

          -  Acute confusion due to systemic illnesses or drug intoxication.

          -  Major depression

          -  Features compatible with &quot;Probable Vascular dementia.

          -  Patient who is pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chon-Haw Tsai, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, China Medical University Hospital, Taichung, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China Medical University Hospital/Neuro Depart.</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2013</study_first_posted>
  <results_first_submitted>May 13, 2013</results_first_submitted>
  <results_first_submitted_qc>August 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2013</results_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Chon-Haw Tsai</investigator_full_name>
    <investigator_title>The Chief, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>dementia</keyword>
  <keyword>NMDA</keyword>
  <keyword>event related potential</keyword>
  <keyword>Bereitschaftspotential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of recruitment period: 05-Aug-2010 to 08-Jun-2012 Type of location: Hospital, Medical China Universities, Neurology clinic.</recruitment_details>
      <pre_assignment_details>The diagnosis of PD-D was based on the criteria proposed by 2007 movement disorders PD-D task force. 30 patients were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sarcosine Capsule</title>
          <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Capsule</title>
          <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sarcosine Capsule</title>
          <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Capsule</title>
          <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.3" spread="5.3"/>
                    <measurement group_id="B2" value="77.3" spread="6.6"/>
                    <measurement group_id="B3" value="76.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks.</title>
        <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks.</time_frame>
        <population>The Intent-to-Treat (ITT) Population comprised all randomised patients who took at least one dose of study medication or placebo and who had a valid baseline efficacy measure and at least one post-baseline efficacy measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks.</title>
          <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms.</description>
          <population>The Intent-to-Treat (ITT) Population comprised all randomised patients who took at least one dose of study medication or placebo and who had a valid baseline efficacy measure and at least one post-baseline efficacy measure.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="21.8"/>
                    <measurement group_id="O2" value="66.7" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1(2-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="20.9"/>
                    <measurement group_id="O2" value="65.2" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="22.5"/>
                    <measurement group_id="O2" value="67.6" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8-week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="25.1"/>
                    <measurement group_id="O2" value="68.3" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognitive Abilities Screening Instrument (CASI) From Baseline to 8 Weeks.</title>
        <description>The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognitive Abilities Screening Instrument (CASI) From Baseline to 8 Weeks.</title>
          <description>The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" spread="23.8"/>
                    <measurement group_id="O2" value="63.9" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" spread="21.8"/>
                    <measurement group_id="O2" value="63.9" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="24.0"/>
                    <measurement group_id="O2" value="63.9" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Dementia Rating (CDR) From Baseline to 8 Weeks.</title>
        <description>The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment &amp; Problem Solving, Community Affairs, Home &amp; Hobbies, and Personal Care. With a higher score indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Dementia Rating (CDR) From Baseline to 8 Weeks.</title>
          <description>The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment &amp; Problem Solving, Community Affairs, Home &amp; Hobbies, and Personal Care. With a higher score indicating more severe symptoms.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.1"/>
                    <measurement group_id="O2" value="1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.0"/>
                    <measurement group_id="O2" value="1.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.1"/>
                    <measurement group_id="O2" value="1.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neuropsychiatry Inventory (NPI) From Baseline to 8 Weeks.</title>
        <description>The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neuropsychiatry Inventory (NPI) From Baseline to 8 Weeks.</title>
          <description>The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="13.4"/>
                    <measurement group_id="O2" value="14.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1(2weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="13.3"/>
                    <measurement group_id="O2" value="14.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="13.9"/>
                    <measurement group_id="O2" value="11.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="13.6"/>
                    <measurement group_id="O2" value="13.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) From Baseline to 8 Weeks.</title>
        <description>The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) From Baseline to 8 Weeks.</title>
          <description>The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="7.6"/>
                    <measurement group_id="O2" value="7.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1(2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="7.9"/>
                    <measurement group_id="O2" value="5.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="8.1"/>
                    <measurement group_id="O2" value="6.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="8.8"/>
                    <measurement group_id="O2" value="6.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 8 Weeks.</title>
        <description>The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 8 Weeks.</title>
          <description>The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="8.0"/>
                    <measurement group_id="O2" value="7.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1(2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="7.7"/>
                    <measurement group_id="O2" value="7.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="7.6"/>
                    <measurement group_id="O2" value="7.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="7.4"/>
                    <measurement group_id="O2" value="7.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory-II (BDI-II) From Baseline to 8 Weeks.</title>
        <description>The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory-II (BDI-II) From Baseline to 8 Weeks.</title>
          <description>The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="10.1"/>
                    <measurement group_id="O2" value="9.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1(2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="9.7"/>
                    <measurement group_id="O2" value="10.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="11.2"/>
                    <measurement group_id="O2" value="10.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="11.7"/>
                    <measurement group_id="O2" value="9.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in The 39-item Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 8 Weeks.</title>
        <description>The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms.</description>
        <time_frame>baseline to 8 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Sarcosine Capsule</title>
            <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsule</title>
            <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in The 39-item Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 8 Weeks.</title>
          <description>The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms.</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="28.2"/>
                    <measurement group_id="O2" value="64.8" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1(2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="29.3"/>
                    <measurement group_id="O2" value="60.9" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2(4 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" spread="26.4"/>
                    <measurement group_id="O2" value="60.9" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3(8 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" spread="28.9"/>
                    <measurement group_id="O2" value="60.1" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Brain Imaging by 18F-FDG PET From Baseline to 8 Weeks.</title>
        <description>18F-FDG PET scan : 8 patients for treatment and placebo groups,respectively.</description>
        <time_frame>baseline to 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Brain Imaging by [99mTc]TRODAT-1 From Baseline to 8 Weeks.</title>
        <description>[99mTc]TRODAT-1 : 7 patients for treatment and placebo groups, respectively.</description>
        <time_frame>baseline to 8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sarcosine Capsule</title>
          <description>Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Capsule</title>
          <description>Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>The chief, Department of Neurology</name_or_title>
      <organization>China Medical University Hospital</organization>
      <phone>8864-22052121 ext 5035</phone>
      <email>d8079@mail.cmuh.org.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

